These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 8206192)
41. Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management. Fritzen K; Basinska K; Rubio-Almanza M; Nicolucci A; Kennon B; Vergès B; Zakrzewska K; Schnell O J Diabetes Sci Technol; 2019 Nov; 13(6):1112-1122. PubMed ID: 30917691 [TBL] [Abstract][Full Text] [Related]
42. Analysis of direct cost of standard compared with intensive insulin treatment of insulin-dependent diabetes mellitus and cost of complications. Stern Z; Levy R Acta Diabetol; 1996 Mar; 33(1):48-52. PubMed ID: 8777285 [TBL] [Abstract][Full Text] [Related]
43. Pharmacological treatment of diabetic patients with cardiovascular complications. Sawicki PT; Berger M J Intern Med; 1998 Mar; 243(3):181-9. PubMed ID: 9627154 [TBL] [Abstract][Full Text] [Related]
44. [The epidemiology and cost/effectiveness analysis of diabetic angiopathy in vascular surgery]. Reparaz L; Martínez I; Ligero JM; Landaluce M; Galindo A; Hernández A; Jiménez Cossío JA Angiologia; 1992; 44(6):225-33. PubMed ID: 1285581 [No Abstract] [Full Text] [Related]
45. Evaluation of drug usage and expenditure in a hospital diabetes clinic. Wu SY; Lung BC; Chang S; Lee SC; Critchley JA; Chan JC J Clin Pharm Ther; 1998 Feb; 23(1):49-56. PubMed ID: 9756112 [TBL] [Abstract][Full Text] [Related]
46. [Arterial hypertension in diabetes mellitus. Etiopathogenesis and treatment]. Menezes I Acta Med Port; 1989 Sep; Suppl 1():43S-44S. PubMed ID: 2694777 [TBL] [Abstract][Full Text] [Related]
47. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study. Heinze G; Hronsky M; Reichardt B; Baumgärtel C; Müllner M; Bucsics A; Winkelmayer WC Appl Health Econ Health Policy; 2015 Apr; 13(2):193-205. PubMed ID: 25536928 [TBL] [Abstract][Full Text] [Related]
48. Pathophysiology and management of hypertension in diabetes. Tuck ML; Corry DB Annu Rev Med; 1991; 42():533-48. PubMed ID: 2035993 [TBL] [Abstract][Full Text] [Related]
49. The "cost" of treating to target: cross-sectional analysis of patients with poorly controlled type 2 diabetes in Australian general practice. Furler J; Hii JW; Liew D; Blackberry I; Best J; Segal L; Young D BMC Fam Pract; 2013 Mar; 14():32. PubMed ID: 23510207 [TBL] [Abstract][Full Text] [Related]
50. [Hypertension in patients with insulin dependent diabetes: examination of selected epidemiologic and pathophysiologic problems]. Czech A Pol Tyg Lek; 1991 Jan 7-14; 46(1-3):43-5. PubMed ID: 1845666 [No Abstract] [Full Text] [Related]
52. [Type 2 diabetes in France: epidemiology, trends of medical care, social and economic burden]. Druet C; Bourdel-Marchasson I; Weill A; Eschwege E; Penfornis A; Fosse S; Fournier C; Chantry M; Attali C; Lecomte P; Simon D; Poutignat N; Gautier A; Risse M; Fagot-Campagna A Presse Med; 2013 May; 42(5):830-8. PubMed ID: 23566620 [TBL] [Abstract][Full Text] [Related]
53. Cerebrovascular challenges in diabetic patients: the pressure is on to maintain perfusion. Barnes JN; Joyner MJ Hypertension; 2011 Apr; 57(4):674-5. PubMed ID: 21357273 [No Abstract] [Full Text] [Related]
54. [Type 2 diabetic patients with hypertension: do they prefer treating diabetes or hypertension?]. El Aassri H; El Mghari G; El Ansari N Pan Afr Med J; 2014; 17():193. PubMed ID: 25396019 [TBL] [Abstract][Full Text] [Related]
55. [Pharmaco-economics of type 2 diabetes]. Scheen AJ; Lefèbvre PJ Rev Med Liege; 1998 May; 53(5):285-9. PubMed ID: 9689884 [TBL] [Abstract][Full Text] [Related]
56. A differing view of treatment of hypertension in patients with diabetes mellitus. Kaplan NM; Rosenstock J; Raskin P Arch Intern Med; 1987 Jun; 147(6):1160-2. PubMed ID: 3592882 [No Abstract] [Full Text] [Related]
57. Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy. Aoki TT; Grecu EO; Prendergast JJ; Arcangeli MA; Meisenheimer R Diabetes Care; 1995 Sep; 18(9):1260-5. PubMed ID: 8612440 [TBL] [Abstract][Full Text] [Related]
58. Statement on hypertension in diabetes mellitus. The Working Group on Hypertension in Diabetes. Arch Intern Med; 1987 Jun; 147(6):1165-6. PubMed ID: 3592883 [No Abstract] [Full Text] [Related]
59. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Schaars CF; Denig P; Kasje WN; Stewart RE; Wolffenbuttel BH; Haaijer-Ruskamp FM Diabetes Care; 2004 Jan; 27(1):123-8. PubMed ID: 14693977 [TBL] [Abstract][Full Text] [Related]
60. The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties. 2. Protective activity of S 1702 on the microvascular system in normal and diabetic rats. Duhault J; Lebon F Arzneimittelforschung; 1972 Oct; 22(10):1686-90. PubMed ID: 4677057 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]